Sacramento doctor: If not for NIH funding, I wouldn’t have survived my leukemia diagnosis | Opinion
My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...
Oncology Nurse Advisor14h
Test Can Predict Post-HCT Relapse in AML and MDS
Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.
Medscape11d
AML: Monitor Early Measurable Residual Disease to Optimize Outcomes
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
Us Weekly8h
Jon Batiste Shares Update on Wife Suleika Jaouad’s Cancer Treatment Following Third Leukemia Diagnosis
Jon Batiste shared a positive update on his wife Suleika Jaouad's health following her September 2024 announcement that she'd ...
Targeted Oncology1d
Orca-T Improves cGVHD-Free Survival Across Hematologic Malignancies
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
CURE12h
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
The American Journal of Managed Care4d
Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML
The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...
BioPharma Dive1d
Orca Bio to seek approval of T cell transplant after positive trial data
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...